Labcorp Holdings 관리

관리 기준 확인 2/4

Labcorp Holdings CEO는 Adam Schechter, Nov2019 에 임명되었습니다 의 임기는 5.5 년입니다. 총 연간 보상은 $ 19.33M, 7.3% 로 구성됩니다. 7.3% 급여 및 92.7% 보너스(회사 주식 및 옵션 포함). 는 MX$ 477.92M 가치에 해당하는 회사 주식의 0.12% 직접 소유합니다. 477.92M. 경영진과 이사회의 평균 재임 기간은 각각 3.2 년과 10.2 년입니다.

주요 정보

Adam Schechter

최고 경영자

US$19.3m

총 보상

CEO 급여 비율	7.33%
CEO 임기	5.5yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	3.2yrs
이사회 평균 재임 기간	10.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Adam Schechter 의 보수는 Labcorp Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2025	n/a	n/a	US$731m
Dec 31 2024	US$19m	US$1m	US$746m
Sep 30 2024	n/a	n/a	US$436m
Jun 30 2024	n/a	n/a	US$450m
Mar 31 2024	n/a	n/a	US$399m
Dec 31 2023	US$16m	US$1m	US$379m
Sep 30 2023	n/a	n/a	US$583m
Jun 30 2023	n/a	n/a	US$677m
Mar 31 2023	n/a	n/a	US$789m
Dec 31 2022	US$15m	US$1m	US$1b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$21m	US$1m	US$2b
Sep 30 2021	n/a	n/a	US$3b
Jun 30 2021	n/a	n/a	US$3b
Mar 31 2021	n/a	n/a	US$3b
Dec 31 2020	US$15m	US$1m	US$2b
Sep 30 2020	n/a	n/a	US$845m
Jun 30 2020	n/a	n/a	US$362m
Mar 31 2020	n/a	n/a	US$321m
Dec 31 2019	US$6m	US$208k	US$824m
Sep 30 2019	n/a	n/a	US$755m
Jun 30 2019	n/a	n/a	US$853m
Mar 31 2019	n/a	n/a	US$896m
Dec 31 2018	US$301k	n/a	US$884m

보상 대 시장: Adam 의 총 보상 ($USD 19.33M )은 MX 시장( $USD 5.53M ).

보상과 수익: Adam 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Adam Schechter (59 yo)

5.5yrs

테뉴어

US$19,327,354

보상

Mr. Adam H. Schechter serves as the President, CEO & Chairman of Laboratory Corporation of America Holdings. Mr. Adam serves as President & Chief Executive Officer at Labcorp Holdings Inc. since November...

리더십 팀

이름	위치	테뉴어	보상	소유권
Adam Schechter	President	5.5yrs	US$19.33m	0.12% MX$ 477.9m
Julia A. Wang	CFO & Executive VP	less than a year	US$3.98m	0.051% MX$ 204.2m
Mark Schroeder	Executive VP	2yrs	US$3.99m	0.0059% MX$ 24.0m
Brian Caveney	EVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer	2yrs	US$3.57m	0.038% MX$ 154.9m
Anita Graham	Executive VP & Chief Human Resources Officer	2.1yrs	US$2.69m	0.00090% MX$ 3.6m
Peter Wilkinson	Senior VP & Chief Accounting Officer	6.1yrs	데이터 없음	0.0024% MX$ 9.9m
Akinbolade Oyegunwa	Executive VP and Chief Information & Technology Officer	less than a year	데이터 없음	0.0041% MX$ 16.7m
Christin O'Donnell	Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Sandra van der Vaart	Executive VP	6.3yrs	데이터 없음	0.0027% MX$ 10.8m
Amy Summy	EVP, Chief Marketing Officer & Consumer Business Lead	5.2yrs	데이터 없음	0.0063% MX$ 25.6m
Marcia Eisenberg	Enterprise Chief Scientific Officer & Senior VP	no data	데이터 없음	데이터 없음
Deborah Sesok-Pizzini	Chief Medical Officer	4.3yrs	데이터 없음	데이터 없음

3.2yrs

평균 재임 기간

55.5yo

평균 연령

경험이 풍부한 관리: LH * 의 관리팀은 경험 ( 3.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Adam Schechter	President	12.1yrs	US$19.33m	0.12% MX$ 477.9m
Peter Neupert	Independent Director	12.3yrs	US$330.00k	0.015% MX$ 62.3m
Kerrii Anderson	Independent Director	19yrs	US$330.00k	0.016% MX$ 63.6m
Garheng Kong	Lead Independent Director	11.4yrs	US$395.00k	0.015% MX$ 62.0m
Richelle Parham	Independent Director	9.3yrs	US$350.00k	0.011% MX$ 45.8m
D. Gilliland	Independent Director	11.1yrs	US$330.00k	0.010% MX$ 41.8m
Jeffrey Davis	Independent Director	5.4yrs	US$355.00k	0.0054% MX$ 22.0m
Paul Rothman	Independent Director	1.9yrs	US$341.43k	0.0020% MX$ 8.1m
Kathryn Wengel	Independent Director	4.2yrs	US$330.00k	0.0039% MX$ 15.6m
Kirsten Kliphouse	Independent Director	2.6yrs	US$330.00k	0.0027% MX$ 10.9m

10.2yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: LH * 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.2 년).

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/05/31 09:46
장 마감 주가	2025/05/09 00:00
수익	2025/03/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Labcorp Holdings Inc. 50 애널리스트 중 18 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Jasper Hellweg	Argus Research Company
Brian Kemp Dolliver	Avondale Partners
Eric Coldwell	Baird

Labcorp Holdings 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Executive VP recently sold Mex$8.9m worth of stock

Labcorp Holdings Inc., Annual General Meeting, May 15, 2025

Independent Director recently sold Mex$2.6m worth of stock

Executive VP recently sold Mex$6.8m worth of stock

Labcorp Holdings Inc. Announces Chief Financial Officer Changes

CFO & Executive VP recently sold Mex$63m worth of stock

Recent updates

Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research

Executive VP recently sold Mex$8.9m worth of stock

First quarter 2025 earnings released: EPS: US$2.55 (vs US$2.71 in 1Q 2024)

Labcorp Holdings Inc. Reaffirms Earnings Guidance for the Year 2025

Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions

Labcorp Holdings Inc Declares Quarterly Cash Dividend, Payable on June 11, 2025

Labcorp Holdings Inc., Annual General Meeting, May 15, 2025

Labcorp Launches Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease

Labcorp to Offer HPV and STI Self-Collection Options in Labcorp Patient Service Centers and Participating Physician Offices Nationwide

Independent Director recently sold Mex$2.6m worth of stock

Executive VP recently sold Mex$6.8m worth of stock

Labcorp Announces Clinical Availability of Liquid Biopsy Test to Guide Personalized Treatment Plans for Patients with Advanced Solid Tumors

Labcorp Holdings Inc. Provides Earnings Guidance for the Year 2025

Labcorp Holdings Inc. Declares Quarterly Cash Dividend, Payable on March 12, 2025

Labcorp Launches H5 Bird Flu Test in the U.S., Now Available for Order Through Physicians

Labcorp Holdings Inc. (NYSE:LH) completed the acquisition of Select Outreach Services of Ballad Health.

Labcorp Holdings Inc. Announces Chief Financial Officer Changes

Third quarter 2024 earnings released: EPS: US$2.02 (vs US$2.12 in 3Q 2023)

Labcorp Holdings Inc. Updates Earnings Guidance for the Year 2024

Labcorp Expands Sexually Transmitted Infection Test Offerings with Rapid Syphilis Test

Labcorp Holdings Inc. to Report Q3, 2024 Results on Oct 24, 2024

Labcorp Holdings Inc. (NYSE:LH) agreed to acquire 15% stake in SYNLAB AG (HMSE:SYAB) from Cinven Limited for €140 million.

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of an Asset Purchase Agreement to acquire Select Assets of BioReference Health, LLC for approximately $240 million.

Upcoming dividend of US$0.72 per share

CFO & Executive VP recently sold Mex$63m worth of stock

Insider recently sold Mex$54m worth of stock

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Substantially all Assets of Invitae Corporation (OTCPK:NVTA.Q).

Second quarter 2024 earnings released: EPS: US$2.44 (vs US$1.75 in 2Q 2023)

Labcorp Holdings Inc. Receives FDA De Novo Marketing Authorization for Pgdx Elio™ Plasma Focus Dx

Labcorp Holdings Inc. Revises Financial Guidance for the Full Year 2024

Labcorp Declares Quarterly Cash Dividend, Payable on September 13, 2024

Labcorp Holdings Inc. to Report Q2, 2024 Results on Aug 01, 2024

Labcorp Launches Labcorp Global Trial Connect to Accelerate Clinical Trials

Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio

Executive VP recently sold Mex$7.1m worth of stock

Dividend of US$0.72 announced

Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy

Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

Labcorp Declares Quarterly Dividend, Payable on June 12, 2024

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Laboratory Corporation of America Holdings, Annual General Meeting, May 14, 2024

Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

Labcorp Launches Weight Loss Management Testing Solutions

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on March 13, 2024

Labcorp Announces the Launch and Availability of A New, FDA-Cleared Blood Test for Risk Assessment and Clinical Management of Severe Preeclampsia

Laboratory Corporation of America Holdings to Report Q4, 2023 Results on Feb 15, 2024

Labcorp Declares Quarterly Cash Dividend, Payable on March 13, 2024

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory business from Legacy Health System Insurance Company.

Geneoscopy, Inc. Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool Rna (Mt-Srna) Colorectal Cancer Screening Test

Labcorp Declares a Cash Dividend, Payable on December 12, 2023

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Outreach Laboratory Business of Baystate Health, Inc.

Laboratory Corporation of America Holdings to Report Q3, 2023 Results on Oct 26, 2023

Independent Director recently sold Mex$18m worth of stock

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach Laboratory Business and Select Operating Assets from Tufts Medicine, Inc.

Upcoming dividend of US$0.72 per share at 1.3% yield

Second quarter 2023 earnings released: EPS: US$1.75 (vs US$3.89 in 2Q 2022)

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on September 8, 2023

Laboratory Corporation of America Holdings acquired Clinical Laboratory Division from Enzo Biochem, Inc. for approximately $115 million.

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory services assets of Jefferson Health.

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach laboratory business from Legacy Health System Insurance Company.

Laboratory Corporation of America Holdings to Report Q2, 2023 Results on Jul 27, 2023

Laboratory Corporation of America Holdings Appoints Paul B. Rothman as a Member of the Board

Laboratory Corporation of America Holdings Launches Labcorp Plasma Focus

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire the outreach laboratory business and select assets of Providence Health & Services - Oregon.

Laboratory Corporation of America Holdings Appoints Mark S. Schroeder to Executive Vice President, President Diagnostics & Chief Operations Officer